Dresden-based healthtech startup developing MyeloAID, an AI-powered bone marrow diagnostic software that analyzes bone marrow samples faster and more precisely, platform-independent and compatible with existing microscopes and scanners. Focused on blood cancer diagnostics and digital biomarkers to improve precision medicine for hematology patients.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €2.5 M | Jan, 2026 | seed |
Frequently Asked Questions
Where is Cancilico located?
Cancilico is located in Dresden, Germany.
What industries does Cancilico operate in?
Cancilico operates in the following industries: healthtech, diagnostics, artificial intelligence, biotech.
When was Cancilico founded?
Cancilico was founded on 2026-01-21.
How much total funding has Cancilico raised?
Cancilico has raised a total of $2,500,000.
Who are the investors in Cancilico?
The investors in Cancilico are: High-Tech Gründerfonds (HTGF), TGFS - Technologiegründerfonds Sachsen, GEDAD GmbH, ROI Verwaltungsgesellschaft (Roland Oetker).
Who are the founders of Cancilico?
The founders of Cancilico are: Markus Badstübner, Dr Moritz Middeke, Tim Schmittmann, Sebastian Riechert, Dr Jan Eckardt, Dr Karsten Wendt, Prof. Gerhard Ehninger, Dr. Moritz Middeke, Dr. Jan Eckardt, Dr. Karsten Wendt.